Curcumin exhibited anti-fatty liver properties in Iranian clinical trial

Curcumin-exhibited-anti-fatty-liver-properties-in-Iranian-clinical-trial.jpg
Getty Images / cheche22 (Getty Images/iStockphoto)

Researchers in Iran compared the effects of a curcumin supplement versus placebo in a cohort of obese individuals with non-alcoholic fatty liver disease (NAFLD). They found that the curcumin supplemented participants exhibited improvements at the end of the study.

Curcumin supplementation was associated with an increase in HDL-Cholesterol (often dubbed the ‘good cholesterol’) and a decrease in fat accumulation in the liver, a decrease in waist circumference, and several other biomarkers of inflammation in the liver.

Did you miss our Liver Health Webinar?

You can view it on demand HERE. From supplements for detoxing to medical foods to help with NAFLD (non-alcoholic fatty liver disease) there is plenty of interest in supporting liver function. Which ingredients are leading the charge? How do they work? Do consumers believe in detox and do they ever think about liver health? How do you best communicate the benefits?

The NutraIngredients-USA’s Liver Health Webinar will bring together leading brands and industry stakeholders to discuss this growing area of interest.

CLICK HERE TO REGISTER & LISTEN ON-DEMAND

The researchers, affiliated with the Tehran University of Medical Sciences, National Iranian Oil Company Central Hospital, Alborz University of Medical Sciences, and the Baqiyatallah University of Medical Sciences, looked specifically at the potential benefits of nano-curcumin, developed to increase the bioavailability of the active compound found in turmeric.

“Since there are no medications to combat it, the role of nutrition is a key treatment factor,” they wrote in their report, published earlier this year in Nutrition and Metabolism. “By examining dietary components such as curcumin for NAFLD improvement, researchers can begin to uncover new treatments.”

Study details

Participants were overweight or obese individuals with NAFLD (as measured using ultrasonography) at the National Iranian Oil Company Central Hospital in Tehran.

Researchers divided the 84 participants randomly but controlled for sex into two groups. Participants in the active group consumed two 40 mg per day of nanocurcumin in capsule form, one at breakfast and another at dinner, totaling to 80 mg per day.

The placebo group consumed a similar-looking and tasting capsule .

The main outcomes measured were anthropometric (weight, waist circumference), ultrasound test of liver size and fat accumulation, and blood biomarkers.

The investigated supplement, both active and placebo, was provided by Iranian company Exir-Nano-Sina. The active capsule contained the company’s patented Sinacurcumin. Funding was provided by the Tehran University of Medical Sciences.

“This trial was the first to assess the effects of nanocurcumin on serum levels of some important factors related to overweight, obesity, and NAFLD,” the researchers wrote.

“Further trials on effects of curcumin are suggested, involving larger sample sizes, longer durations, non-obese patients, and considering the mentioned limitations.”

Source: Nutrition & Metabolism

Published online ahead of print, https://doi.org/10.1186/s12986-019-0331-1

“Nano-curcumin improves glucose indices, lipids, inflammation, and Nesfatin in overweight and obese patients with non-alcoholic fatty liver disease (NAFLD): a double-blind randomized placebo-controlled clinical trial”

Authors: Seyed Ali Jazayeri-Tehrani, et al.